Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 33 | 2024 | 3623 | 2.580 |
Why?
|
Aminoglycosides | 7 | 2017 | 161 | 1.270 |
Why?
|
fms-Like Tyrosine Kinase 3 | 9 | 2024 | 497 | 1.170 |
Why?
|
Core Binding Factors | 2 | 2019 | 29 | 1.010 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 3 | 2024 | 308 | 0.890 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2019 | 727 | 0.750 |
Why?
|
Fanconi Anemia | 1 | 2022 | 327 | 0.670 |
Why?
|
Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5709 | 0.610 |
Why?
|
Gene Rearrangement | 2 | 2021 | 1139 | 0.590 |
Why?
|
Phenylurea Compounds | 3 | 2022 | 532 | 0.560 |
Why?
|
Cytarabine | 6 | 2021 | 697 | 0.560 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2021 | 697 | 0.540 |
Why?
|
Tandem Repeat Sequences | 3 | 2015 | 182 | 0.540 |
Why?
|
Metformin | 1 | 2022 | 914 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 11843 | 0.440 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2012 | 283 | 0.410 |
Why?
|
Antineoplastic Agents | 7 | 2023 | 13708 | 0.410 |
Why?
|
Niacinamide | 1 | 2015 | 419 | 0.410 |
Why?
|
Perceptual Masking | 1 | 2010 | 90 | 0.350 |
Why?
|
Child Language | 1 | 2010 | 62 | 0.350 |
Why?
|
Competitive Behavior | 1 | 2010 | 78 | 0.340 |
Why?
|
Child | 43 | 2024 | 80863 | 0.330 |
Why?
|
Verbal Learning | 1 | 2010 | 465 | 0.300 |
Why?
|
Genes, Wilms Tumor | 3 | 2013 | 92 | 0.290 |
Why?
|
Mutation | 9 | 2024 | 30243 | 0.260 |
Why?
|
Myelodysplastic Syndromes | 3 | 2022 | 1400 | 0.250 |
Why?
|
Child, Preschool | 26 | 2024 | 42623 | 0.250 |
Why?
|
Torque teno virus | 1 | 2024 | 13 | 0.230 |
Why?
|
Infant | 23 | 2024 | 36497 | 0.230 |
Why?
|
Phthalimides | 1 | 2024 | 34 | 0.230 |
Why?
|
Piperidones | 1 | 2024 | 37 | 0.230 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2024 | 317 | 0.220 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2023 | 37 | 0.220 |
Why?
|
Antigens, CD | 2 | 2012 | 4029 | 0.220 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2020 | 631 | 0.210 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2017 | 495 | 0.210 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 249 | 0.200 |
Why?
|
Leukemia | 3 | 2024 | 1527 | 0.200 |
Why?
|
Recurrence | 9 | 2022 | 8510 | 0.200 |
Why?
|
Indenes | 1 | 2021 | 59 | 0.180 |
Why?
|
Morpholines | 1 | 2024 | 583 | 0.180 |
Why?
|
Polycythemia | 1 | 2021 | 124 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2020 | 1557 | 0.180 |
Why?
|
Prognosis | 15 | 2024 | 30028 | 0.180 |
Why?
|
Exons | 3 | 2019 | 2392 | 0.180 |
Why?
|
Adolescent | 28 | 2024 | 89168 | 0.180 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2024 | 1438 | 0.170 |
Why?
|
Paraganglioma | 1 | 2021 | 143 | 0.170 |
Why?
|
Anthracyclines | 1 | 2021 | 286 | 0.160 |
Why?
|
Remission Induction | 2 | 2022 | 2408 | 0.160 |
Why?
|
Disease-Free Survival | 8 | 2021 | 6856 | 0.160 |
Why?
|
Vidarabine | 1 | 2020 | 337 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2023 | 687 | 0.160 |
Why?
|
Neoplastic Stem Cells | 1 | 2006 | 1357 | 0.150 |
Why?
|
Quinolines | 1 | 2023 | 769 | 0.150 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1014 | 0.150 |
Why?
|
Treatment Outcome | 21 | 2023 | 65409 | 0.140 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 544 | 0.140 |
Why?
|
Young Adult | 18 | 2024 | 60045 | 0.140 |
Why?
|
Leukemia, Myeloid | 2 | 2010 | 693 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5709 | 0.130 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 736 | 0.130 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 245 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1614 | 0.130 |
Why?
|
Humans | 49 | 2024 | 768451 | 0.130 |
Why?
|
Azacitidine | 1 | 2017 | 336 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1143 | 0.120 |
Why?
|
Gene Duplication | 1 | 2015 | 314 | 0.120 |
Why?
|
Infant, Newborn | 10 | 2021 | 26395 | 0.110 |
Why?
|
Central Nervous System Infections | 1 | 2014 | 61 | 0.110 |
Why?
|
Male | 31 | 2024 | 364781 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 210 | 0.110 |
Why?
|
Female | 33 | 2024 | 396943 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2019 | 16029 | 0.110 |
Why?
|
Public Sector | 1 | 2015 | 265 | 0.110 |
Why?
|
Transplantation Conditioning | 2 | 2022 | 1598 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2024 | 2834 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4534 | 0.100 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.090 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2011 | 176 | 0.090 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2016 | 365 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2017 | 12813 | 0.090 |
Why?
|
Lymphoma | 1 | 2020 | 1907 | 0.090 |
Why?
|
Hematologic Neoplasms | 2 | 2020 | 1905 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2016 | 867 | 0.090 |
Why?
|
Vocabulary | 1 | 2010 | 167 | 0.080 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2013 | 656 | 0.080 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 230 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2020 | 5904 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2014 | 761 | 0.080 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8051 | 0.070 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2009 | 288 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1602 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3941 | 0.070 |
Why?
|
Tumor Stem Cell Assay | 1 | 2006 | 116 | 0.070 |
Why?
|
Decision Making | 1 | 2020 | 3961 | 0.070 |
Why?
|
Program Evaluation | 1 | 2015 | 2508 | 0.070 |
Why?
|
Alleles | 3 | 2019 | 6890 | 0.070 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 352 | 0.070 |
Why?
|
Etoposide | 2 | 2017 | 640 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2012 | 964 | 0.060 |
Why?
|
Erythroid Precursor Cells | 1 | 2006 | 212 | 0.060 |
Why?
|
Adult | 15 | 2024 | 223542 | 0.060 |
Why?
|
Graft vs Host Disease | 2 | 2015 | 3042 | 0.060 |
Why?
|
Retrospective Studies | 10 | 2020 | 81834 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2024 | 1869 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 892 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9425 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1395 | 0.060 |
Why?
|
Antigens, CD34 | 1 | 2006 | 656 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 5 | 2013 | 6537 | 0.060 |
Why?
|
Risk Factors | 5 | 2021 | 74915 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2742 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1062 | 0.050 |
Why?
|
DNA Methylation | 1 | 2017 | 4421 | 0.050 |
Why?
|
Patient Discharge | 1 | 2016 | 3471 | 0.050 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 17149 | 0.050 |
Why?
|
Normetanephrine | 1 | 2021 | 25 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40271 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 3077 | 0.050 |
Why?
|
Survival Analysis | 2 | 2014 | 10125 | 0.050 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
Busulfan | 1 | 2021 | 259 | 0.040 |
Why?
|
Genotype | 4 | 2019 | 13047 | 0.040 |
Why?
|
Transplantation, Homologous | 2 | 2022 | 4834 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2012 | 12561 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1195 | 0.040 |
Why?
|
United States | 4 | 2022 | 73121 | 0.040 |
Why?
|
Transcription Factors | 2 | 2024 | 12174 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 24311 | 0.040 |
Why?
|
Psychotic Disorders | 1 | 2015 | 3278 | 0.040 |
Why?
|
Prospective Studies | 2 | 2016 | 54914 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7471 | 0.040 |
Why?
|
Adrenal Glands | 1 | 2021 | 557 | 0.040 |
Why?
|
Asparaginase | 1 | 2020 | 240 | 0.040 |
Why?
|
Prevalence | 3 | 2010 | 15880 | 0.040 |
Why?
|
Nitriles | 1 | 2023 | 984 | 0.040 |
Why?
|
Anemia, Aplastic | 1 | 2020 | 231 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2023 | 1094 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7956 | 0.040 |
Why?
|
Daunorubicin | 1 | 2017 | 157 | 0.040 |
Why?
|
Vincristine | 1 | 2020 | 1039 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3611 | 0.030 |
Why?
|
Reference Standards | 1 | 2020 | 1015 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 252 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9623 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12875 | 0.030 |
Why?
|
Neoplasms | 3 | 2018 | 22386 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3278 | 0.030 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2016 | 168 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2016 | 248 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4586 | 0.030 |
Why?
|
Community Mental Health Centers | 1 | 2015 | 93 | 0.030 |
Why?
|
Hospitalization | 1 | 2015 | 10845 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2010 | 8635 | 0.030 |
Why?
|
Chromosome Duplication | 1 | 2014 | 76 | 0.030 |
Why?
|
Transplantation | 1 | 2016 | 221 | 0.030 |
Why?
|
Ribavirin | 1 | 2016 | 395 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1749 | 0.030 |
Why?
|
Critical Pathways | 1 | 2018 | 476 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1604 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2018 | 499 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2006 | 3408 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2014 | 434 | 0.030 |
Why?
|
Pilot Projects | 2 | 2020 | 8730 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 1142 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1277 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.030 |
Why?
|
Bone Marrow | 2 | 2016 | 2929 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 2013 | 323 | 0.030 |
Why?
|
Homozygote | 1 | 2017 | 1779 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 729 | 0.020 |
Why?
|
Dexamethasone | 1 | 2020 | 1965 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4041 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3665 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 672 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4120 | 0.020 |
Why?
|
Observer Variation | 1 | 2017 | 2622 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 751 | 0.020 |
Why?
|
Heterozygote | 1 | 2017 | 2792 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 829 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 132 | 0.020 |
Why?
|
Electronic Health Records | 2 | 2017 | 4877 | 0.020 |
Why?
|
Acute Disease | 2 | 2010 | 7246 | 0.020 |
Why?
|
Karyotyping | 1 | 2010 | 1173 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1607 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2010 | 18048 | 0.020 |
Why?
|
Clone Cells | 1 | 2011 | 1672 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2011 | 1840 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39430 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5803 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2011 | 2525 | 0.020 |
Why?
|
Neutrophils | 1 | 2018 | 3790 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5880 | 0.010 |
Why?
|
Mortality | 1 | 2016 | 2917 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3826 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2011 | 2415 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2016 | 3063 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7605 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3858 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2009 | 3790 | 0.010 |
Why?
|
Length of Stay | 1 | 2016 | 6521 | 0.010 |
Why?
|
Patient Readmission | 1 | 2016 | 3308 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4213 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5342 | 0.010 |
Why?
|
Cohort Studies | 2 | 2016 | 41797 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13324 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6527 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20231 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10358 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 4249 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23638 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3265 | 0.010 |
Why?
|
Middle Aged | 2 | 2024 | 223418 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36840 | 0.010 |
Why?
|